PRDM2
PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.
Overview
S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor. Binds to the macrophage-specific TPA-responsive element (MTE) of the HMOX1 (heme oxygenase 1) gene and may act as a transcriptional activator of this gene.
IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Hepatocellular Carcinoma, Neuroblastoma, Papillary Renal Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.
- 1 · What it is
PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.
- 2 · What goes wrong in cancer
S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor.
- 3 · How drugs use it
No product in this corpus aims at PRDM2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:9347 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13029 (protein name, function text, keywords and locations (REST API)); IntOGen PRDM2 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor. Binds to the macrophage-specific TPA-responsive element (MTE) of the HMOX1 (heme oxygenase 1) gene and may act as a transcriptional activator of this gene. Location: Nucleus (UniProt). Locus 1p36.21 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
- Neuroblastoma: IntOGen driver in 1 cohort (NBL)
- Papillary renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PRDM2" OR ABSTRACT:"PRDM2" OR TITLE:"PR/SET domain 2" OR ABSTRACT:"PR/SET domain 2" OR TITLE:"PR domain zinc finger protein 2" OR ABSTRACT:"PR domain zinc finger protein 2" OR TITLE:"RIZ1" OR ABSTRACT:"RIZ1" OR TITLE:"RIZ2" OR ABSTRACT:"RIZ2" OR TITLE:"KMT8" OR ABSTRACT:"KMT8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRDM2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCUL3
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetHNF1A
Shares Papillary renal cell carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, IntOGen.
- TargetMYO5A
Shares Neuroblastoma (paediatric), Hepatocellular carcinoma, IntOGen.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Papillary renal cell carcinoma, Renal cell carcinoma.
- TargetFBN2
Shares Neuroblastoma (paediatric), IntOGen.
- TargetPRUNE2
Shares Neuroblastoma (paediatric), IntOGen.
- TargetSGK1
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetPCBP1
Shares Papillary renal cell carcinoma, Renal cell carcinoma, IntOGen.